Gulati, Nicholas http://orcid.org/0000-0002-4347-0710
Donnelly, Douglas
Qian, Yingzhi
Moran, Una
Johannet, Paul
Zhong, Judy
Osman, Iman
Funding for this research was provided by:
New York University Melanoma SPORE (P50CA225450)
National Institutes of Health (PQ8 R01CA231295)
Article History
Received: 23 August 2020
Accepted: 5 November 2020
First Online: 11 November 2020
Ethics approval and consent to participate
: The patient data used in this manuscript come from patients who were prospectively enrolled in two institutional review board-approved databases at NYU Langone Health (institutional review board #10362 and #S16-00122). Biospecimens, clinicopathological data, and follow‐up information are collected using developed protocols and Standard Operating Procedure (SOP). Upon consent, each patient is assigned a unique identification number. From review of patients’ medical records, trained data managers capture clinical and pathological information in 335 fields in the REDCap database. Physicians in the New York University Departments of Dermatology, Pathology, Surgery, and Oncology, as well as biostatisticians, were involved in the design of the database and the definitions of the data collection fields. Demographic background, personal and family history of disease, pathological diagnoses, radiological imaging reports, sentinel lymph node mapping, disease staging, treatment, and continuing clinical follow‐up information, all compiled from thorough review of medical records and clinician interview, are incorporated into the database. Neither the name nor identifying information for an individual patient is used in program publications.
: Not applicable.
: The authors declare that they have no competing interests.